Sequential Therapy for Helicobacter pylori Infection in Treatment-naïve Children.

Unlabelled: The goal of first-line Helicobacter pylori therapy is to reach an eradication rate of 90% to avoid further investigations, antibiotic use, and spreading of resistant strains.

Aim: To evaluate the eradication rate of high-dose sequential therapy in treatment-naïve children and to assess factors associated with failure.

Methods: Prospective data assessed in a registry from nine European centers between October 2009 and December 2011.

Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study.

Objective: Faecal calprotectin is used as a sensitive marker for gastrointestinal mucosal inflammation. We compared the performance of three different assays in a large cohort of symptomatic paediatric patients.

Design: Retrospective monocentric study.

Whey- vs casein-based enteral formula and gastrointestinal function in children with cerebral palsy.

Objectives: Children with severe cerebral palsy (CP) commonly have gastrointestinal (GI) dysfunction. Whey-based enteral formulas have been postulated to reduce gastroesophageal reflux (GOR) and accelerate gastric emptying (GE). The authors investigated whether whey-based (vs casein-based) enteral formulas reduce GOR and accelerate GE in children who have severe CP with a gastrostomy and fundoplication.

Optimisation of the reflux-symptom association statistics for use in infants being investigated by 24-hour pH impedance.

Background And Aim: pH-impedance monitoring is used to diagnose symptomatic gastroesophageal reflux (GER) based on symptom association probability (SAP). Current criteria for calculation of SAP are optimised for heartburn in adults. Infants, however, demonstrate a different symptom profile.

Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children.

The aim of the present study was to evaluate the Helicobacter pylori ClariRes assay (Ingenetix, Vienna, Austria) for the detection of H. pylori infection and the simultaneous clarithromycin susceptibility testing of the H. pylori isolates in stool samples from 100 symptomatic children.